Impact of hormone therapy on acute radiotherapy toxicity in the treatment of prostate cancer

Prostate Cancer and Prostatic Diseases

Volumn 8, Issue 3, 2005, Pages 224-228

  Jani, A B ^a   Gratzle, J ^a   Myers, M ^a  

^a UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

Author keywords

Androgen ablation; Hormone therapy; Radiotherapy; Toxicity

Indexed keywords

BICALUTAMIDE; FLUTAMIDE; GONADORELIN AGONIST; GOSERELIN; LEUPRORELIN;

ACUTE TOXICITY; AGED; BRACHYTHERAPY; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; EXTERNAL BEAM RADIOTHERAPY; GASTROINTESTINAL TOXICITY; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION SICKNESS; REVIEW; UROGENITAL TRACT DISEASE;

AGED; ANILIDES; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, HORMONAL; BRACHYTHERAPY; COHORT STUDIES; FLUTAMIDE; GASTROINTESTINAL TRACT; GOSERELIN; HORMONES; HUMANS; LEUPROLIDE; MALE; MIDDLE AGED; PROGNOSIS; PROSTATIC NEOPLASMS; RADIATION INJURIES; RADIOTHERAPY; RADIOTHERAPY DOSAGE; REGRESSION ANALYSIS; TESTOSTERONE; TIME FACTORS; TREATMENT OUTCOME; UROGENITAL SYSTEM;

EID: 31044434562     PISSN: 13657852     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.pcan.4500812     Document Type: Review

References (38)

1. Jani AB, Hellman S. Early prostate cancer: Clinical decision-making. Lancet 2003; 361: 1048-1053.
2. Gronberg H. Prostate cancer epidemiology. Lancet 2003; 361: 859-864.
3. Jani AB, Roeske JC, Rash C. Intensity-modulated radiation therapy for prostate cancer. Clin Prostate Cancer 2003; 2: 98-105.
4. Zelefsky MJ et al. High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer. J Urol 2001; 166: 876-881.
5. Pollack A et al. Prostate cancer radiation dose response: Results of the M. D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys 2002; 53: 1097-1105.
6. Huggins C. Endocrine-induced regression of cancers. Science 1967; 156: 1050-1054.
7. Prostate Cancer Trialists' Collaborative Group. Maximum androgen blockade in advanced prostate cancer: An overview of 22 randomised trials with 3283 deaths in 5710 patients. Lancet 1995; 346: 265-269.
8. Prostate Cancer Trialists' Collaborative Group. Maximum androgen blockade in advanced prostate cancer: An overview of the randomised trials. Lancet 2000; 355: 1491-1498.
9. Jani AB. The effectiveness of combining hormone therapy and radiotherapy in the treatment of prostate cancer. Expert Opin Pharmacother 2004; 5: 2469-2477.
10. Pilepich MV et al. Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys 2001; 50: 1243-1252.
11. Laverdiere J et al. Beneficial effect of combination hormonal therapy administered prior and following external beam radiation therapy in localized prostate cancer. Int J Radiat Oncol Biol Phys 1997; 37: 247-252.
12. Lawton CA et al. Updated results of the phase III Radiation Therapy Oncology Group (RTOG) trial 85-31 evaluating the potential benefit of androgen suppression following standard radiation therapy for unfavorable prognosis carcinoma of the prostate. Int J Radiat Oncol Biol Phys 2001; 49: 937-946.
13. Bella M et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): A phase III randomised trial. Lancet 2002; 360: 103-106.
14. Hanks GE et al. Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: The Radiation Therapy Oncology Group Protocol 92-02. J Clin Oncol 2003; 21: 3972-3978.
15. Roach III M et al. Phase III trial comparing whole-pelvic vs prostate-only radiotherapy and neoadjuvant vs adjuvant combined androgen suppression: Radiation Therapy Oncology Group 9413. J Clin Oncol 2003; 21: 1904-1911.
16. Jani AB, Kao J, Hellman S. Hormone therapy adjuvant to external beam radiotherapy for locally advanced prostate carcinoma: A complication-adjusted number-needed-to-treat analysis. Cancer 2003; 98: 2351-2361.
17. D'Amico AV et al. Biochemical outcome following external beam radiation therapy with or without androgen suppression therapy for clinically localized prostate cancer. JAMA 2000; 284: 1280-1283.
18. Jani AB et al. The impact of hormone therapy when combined with external beam radiotherapy for early-stage, intermediate-or high-risk prostate cancer. Am J Clin Oncol 2003; 26: 382-385.
19. Lee LN, Stock RG, Stone NN. Role of hormonal therapy in the management of intermediate- to high-risk prostate cancer treated with permanent radioactive seed implantation. Int J Radiat Oncol Biol Phys 2002; 52: 444-452.
20. D'amico AV et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998; 280: 969-974.
21. Merrick GS et al. Does hormonal manipulation in conjunction with permanent interstitial brachytherapy, with or without supplemental external beam irradiation, improve the biochemical outcome for men with intermediate or high-risk prostate cancer? Br J Urol Int 2003; 91: 23-29.
22. Potters L, Torre T, Ashley R, Leibel S. Examining the role of neoadjuvant androgen deprivation in patients undergoing prostate brachytherapy. J Clin Oncol 2000; 18: 1187-1192.
23. Martinez A et al. No apparent benefit at 5 years from a course of neoadjuvant/concurrent androgen deprivation for patients with prostate cancer treated with a high total radiation dose. J Urol 2003; 170: 2296-2301.
24. Jani AB, Kao J, Heimann R, Hellman S. Hormone therapy and radiotherapy for early prostate cancer: A utility-adjusted number needed to treat (NNT) analysis. Int J Radiat Oncol Biol Phys 2005; 61: 687-694.
25. D'Amico AV et al. 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: A randomized controlled trial. JAMA 2004; 292: 821-827.
26. Holzbeierlein JM, Castle E, Thrasher JB. Complications of androgen deprivation therapy: Prevention and treatment. Oncology 2004; 18: 303-309.
27. Jani AB, Sokoloff M, Shalhav A, Stadler W. Androgen ablation adjuvant to post-prostatectomy radiotherapy: A complication-adjusted number-needed to treat analysis. Urology 2004; 64: 976-981.
28. Valicenti RK et al. RTOG 94-06: Is the addition of neoadjuvant hormonal therapy to dose-escalated 3D conformal radiation therapy for prostate cancer associated with treatment toxicity? Int J Radiat Oncol Biol Phys 2003; 57: 614-620.
29. Zelefsky MJ, Harrison A. Neoadjuvant androgen ablation prior to radiotherapy for prostate cancer: Reducing the potential morbidity of therapy. Urology 1997; 49 (3A Suppl): 38-45.
30. Zelefsky MJ et al. Neoadjuvant hormonal therapy improves the therapeutic ratio in patients with bulky prostatic cancer treated with three-dimensional conformal radiation therapy. Int J Radiat Oncol Biol Phys 1994; 29: 755-761.
31. Sanguineti G et al. Adjuvant androgen deprivation impacts late rectal toxicity after conformal radiotherapy of prostate carcinoma. Br J Cancer 2002; 86: 1843-1847.
32. Forman JD et al. Neoadjuvant hormonal downsizing of localized carcinoma of the prostate: Effects on the volume of normal tissue irradiation. Cancer Invest 1995; 13: 8-15.
33. Blank KR et al. Neoadjuvant androgen deprivation prior to transperineal prostate brachytherapy: Smaller volumes, less morbidity. Cancer J Sci Am 1999; 5: 370-373.
34. Yang FE et al. The potential for normal tissue dose reduction with neoadjuvant hormonal therapy in conformal treatment planning for stage C prostate cancer. Int J Radiat Oncol Biol Phys 1995; 33: 1009-1017.
35. Lee AK et al. Under-dosing of potential microscopic prostate cancer with IMRT after neoadjuvant hormonal therapy. Int J Radiat Oncol Biol Phys 2004; 60: S449.
36. Radiation Therapy Oncology Group (RTOG). Toxicity information. Sections 7-8: Acute and Late Radiation Morbidity Criteria. http://www.rtog.org/members/toxicity/main.html.
37. Dawson-Saunders B, Trapp RG. Basic and Clinical Biostatistics. Prentice-Hall: East Norwalk, CT, 1990.
38. Agresti A. Categorical Data Analysis, 2nd edn. Wiley: New York, NY, 2002.